Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2010
07/27/2010CA2595815C Salt form of a dopamine agonist
07/27/2010CA2546701C Crystalline ammonium salts of rosuvastatin
07/27/2010CA2490826C Stable hydralazine pharmaceutical compositions
07/27/2010CA2481241C Fused quinoxaline derivatives as inhibitors of akt activity
07/27/2010CA2475025C Solid composition for oral or rectal administration having a melting point of 25.degree.c or higher and comprising a mixture of polar glycolipids and non-polar lipids
07/27/2010CA2470105C Substituted 6h-dibenzo[c,h]chromenes as estrogenic agents
07/27/2010CA2466560C Acetylene derivatives having mglur5 antagonistic activity
07/27/2010CA2463084C Preparation and use of carbohydrate-based bicyclic ring structures with antimicrobial and cytostatic activity
07/27/2010CA2461060C Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof
07/27/2010CA2457034C Ophthalmic composition comprising an ascomycin
07/27/2010CA2449854C Aminoacetonitrile compounds for controlling endoparasites
07/27/2010CA2449031C Water-soluble porphyrin derivatives for photodynamic therapy, their use and manufacture
07/27/2010CA2448456C Solid pharmaceutical formulations comprising modafinil
07/27/2010CA2448319C Cytotoxins, prodrugs, linkers and stabilizers useful therefor
07/27/2010CA2445625C Pyrazino'1',2':1,6!pyrido'3,4-b!indole1,4-dione derivatives
07/27/2010CA2444266C Use of bile acid or bile salt fatty acid conjugates
07/27/2010CA2437587C Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1,3-oxazolines and their use as anticoagulant and antithrombotic agents
07/27/2010CA2436659C Cannabinoid receptor ligands
07/27/2010CA2427569C Selective glucocorticoid receptor agonists
07/27/2010CA2404000C A functional assay of high-density lipoprotein
07/27/2010CA2384717C Topical treatment for prevention of ocular infections
07/27/2010CA2373797C Methods of treating or preventing affective disorders
07/27/2010CA2373559C Serotonin transport inhibitors
07/27/2010CA2263152C Immunologically active proteins from borrelia burgdorferi, nucleic acids which encode them, and their use in test kits and as vaccines
07/27/2010CA2236982C The use of lecithin-cholesterol acyltransferase (lcat) in the treatment of atherosclerosis
07/27/2010CA2224080C Relaxin-like factor and methods and uses thereof
07/27/2010CA2223300C Expression of lipoproteins
07/27/2010CA2163337C Novel heparin-like sulfated polysaccharides
07/22/2010WO2010083537A2 Optimal biological marker for the biological potency of emblica officinalis gaertn. (amla) fruit-methods and products thereof
07/22/2010WO2010083501A2 Alpha-helix mimetic using a 2,5-oligopyrimidine scaffold
07/22/2010WO2010083465A1 Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
07/22/2010WO2010083445A1 Use of u18666a compounds for smoking cessation and inhibition of nicotine receptor function
07/22/2010WO2010083444A1 Alpha7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
07/22/2010WO2010083442A1 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
07/22/2010WO2010083436A1 Benzo [c] phenanthridines as antimicrobial agents
07/22/2010WO2010083414A1 Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms therof for the treatment of cancer
07/22/2010WO2010083404A2 Linked myc-max small molecule inhibitors
07/22/2010WO2010083403A1 Fused amino pyridines for the treatment of brain tumors
07/22/2010WO2010083385A2 Compounds for reducing drug resistance and uses thereof
07/22/2010WO2010083384A2 Non-peptidyl, potent, and selective mu opioid receptor antagonists
07/22/2010WO2010083328A2 Methods for screening and compounds that protect against amyloid diseases
07/22/2010WO2010083280A2 Methods for treating obesity and disorders associated with hyperlipidemia in a mammal
07/22/2010WO2010083279A2 Methods for treating disorders associated with hyperlipidemia in a mammal
07/22/2010WO2010083276A1 Novel forms of bendamustine free base
07/22/2010WO2010083264A1 Novel benzenesulfonamides as calcium channel blockers
07/22/2010WO2010083246A1 Fluoroisoquinoline substituted thiazole compounds and methods of use
07/22/2010WO2010083241A2 2,4-pyrimidinediamine compounds for treatment of inflammatory disorders
07/22/2010WO2010083240A2 Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds
07/22/2010WO2010083239A2 Therapeutic modulation of vaginal epithelium boundary lubrication
07/22/2010WO2010083237A2 Composition and methods to manage the inflammatory basis of chronic disease conditions and maintain an optimal immune response in elderly
07/22/2010WO2010083220A1 Benzoxazole inhibitors of poly(adp-ribose)polymerase
07/22/2010WO2010083218A1 Methods of using substituted isoxazolo pyridinones as dissociated glucocorticoids
07/22/2010WO2010083215A2 Composition and method for the treatment of diseases affected by apoptosis
07/22/2010WO2010083207A2 Protein kinase c inhibitors and uses thereof
07/22/2010WO2010083199A1 Benzthiazole inhibitors of poly(adp-ribose)polymerase
07/22/2010WO2010083141A1 Bicyclic compounds for the reduction of beta-amyloid production
07/22/2010WO2010083136A1 Oxadiazole beta carboline derivatives as antidiabetic compounds
07/22/2010WO2010083133A1 Compositions and methods for the treatment of throat discomfort
07/22/2010WO2010083104A2 Conjugates of noscapine and folic acid and their use in treating cancer
07/22/2010WO2010083084A1 Receptor activator of the rank receptor complex inhibitor
07/22/2010WO2010083035A2 Transdermal administration of tamsulosin
07/22/2010WO2010082912A1 Derivatives of multi-ring aromatic compounds and uses as anti-tumor agents
07/22/2010WO2010082863A1 Method and composition for treating multiple sclerosis (variants)
07/22/2010WO2010082858A2 New method for obtaining 5-amino-2,3-dihydrophthalazine-1,4-dione alkali metal salts and their use in medicine
07/22/2010WO2010082855A1 Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation
07/22/2010WO2010082837A1 Medicament for the treatment of pain and inflammation
07/22/2010WO2010082821A1 Method of treating cancer
07/22/2010WO2010082813A1 Method of treating cancer
07/22/2010WO2010082789A2 Anticancer compositions comprising cedrol in nanoparticle form
07/22/2010WO2010082785A2 Oral pharmaceutical composition
07/22/2010WO2010082690A1 Postprandial hyperglycemia-improving agent
07/22/2010WO2010082661A1 1,5-ag-containing composition
07/22/2010WO2010082612A1 Imidazothiazole derivative having proline ring structure
07/22/2010WO2010082601A1 Novel 2,5-disubstituted pyrrole derivative
07/22/2010WO2010082600A1 Agent for maintaining healthy state of periodontal tissue comprising oleuropein and degraded product thereof
07/22/2010WO2010082563A1 Cyclic compound having hetero atom
07/22/2010WO2010082531A1 Active blood coagulation factor inhibitor
07/22/2010WO2010082503A1 Gold complex and medicinal composition containing same
07/22/2010WO2010082390A1 Low-concentration nutritional composition
07/22/2010WO2010082220A2 Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
07/22/2010WO2010082219A2 An arteether injection for treatment of malaria
07/22/2010WO2010082214A2 Fenofibrate formulation with enhanced oral bioavailability
07/22/2010WO2010082212A2 N-biphenylacyl thiazolidine-2,4-dione derivatives, their synthesis and uses
07/22/2010WO2010082205A1 Synergistic combinations of carotenoids and polyphenols
07/22/2010WO2010082182A1 Fulvic acid in combination with fluconazole or amphotericin b for the treatment of fungal infections
07/22/2010WO2010082149A1 Sprm pharmaceutical compositions methods of treatment using them
07/22/2010WO2010082092A1 Propofol based anesthetic with preservative
07/22/2010WO2010082072A1 Process for the preparation of rosuvastatin salts
07/22/2010WO2010082050A1 Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
07/22/2010WO2010082044A1 Unsaturated bicyclic heterocyclic derivatives as smo antagonists
07/22/2010WO2010081984A1 Formulation for oral transmucosal administration of analgesic and/or antispasmodic molecules
07/22/2010WO2010081920A1 Incorporation of an emetic in drugs as a safety system in respect of possible overdoses, particularly in drugs acting on the central nervous system such as benzodiazepine and derivatives, barbiturates... and drugs for paediatric use
07/22/2010WO2010081904A1 4 ( 1h) -pyridinone derivatives and their use as antimalaria agents
07/22/2010WO2010081900A1 Quinolinone derivatives useful for the treatment of cns disorders
07/22/2010WO2010081898A1 Novel benzotriazole derivatives useful for the treatment of cns disorders
07/22/2010WO2010081881A1 Aurora kinase inhibitors compounds.
07/22/2010WO2010081877A1 Nitric oxide furoxan derivative compounds endowed with antitumoral activity
07/22/2010WO2010081862A2 Methods and preparations for protecting critically ill patients
07/22/2010WO2010081859A1 6-phenyl-lh-imidazo [4, 5-c] pyridine-4-carbonitrile derivatives as cathepsin s and/or cathepsin k inhibitors
07/22/2010WO2010081851A1 Piperidin-4-ylpiperazine compounds for the treatment of hcv infection
1 ... 2163 2164 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 ... 7860